Orgenesis Inc.

ORGS Healthcare Biotechnology

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.

0.06 0.06 Infinity
Market cap
$5.7M
P/E
0.0×
Fwd P/E
1.0×
Dividend yield
—
F-score
3/9
Altman Z
−352.42
Beneish M
n/a
Dividend safety
n/a
Nov '17 Dec '17 Nov '18 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24
Piotroski F-Score
— — — — — 5 3 3 1 3
P/E ratio
0.00 0.00 0.00 0.00 5.01 2.00 0.00 0.00 0.00 0.00
P/S ratio
5.40 6.31 5.60 3.05 19.01 12.54 1.97 1.37 26.93 7.69
Altman Z-Score
(1.50) 11.85 (0.31) (0.74) (1.11) (2.73) (0.64) (0.96) (29.89) (352.42)
P/FCF ratio
20.69 24.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(6.51) (7.90) (2.22) (2.85) (2.13) (6.92) (4.63) (2.41) (70.52) (868.26)
Beneish M-Score
(4.52) — (0.54) — — — — (1.20) — —
P/Operating CF
(27.90) (32.61) (15.49) (14.60) (27.40) (2.12) (28.37) (4.57) (28.43) (3.79)
P/B ratio
3.28 3.83 3.01 2.34 12.20 1.82 1.81 1.69 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 3.10 3.80 4.40 0.00 0.00
EV/Sales
5.90 6.81 4.81 2.54 22.19 8.07 2.10 1.69 66.20 23.15
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
16.44 18.98 (5.25) (3.11) (6.54) (0.79) (2.78) (2.44) (2.36) (1.40)
EV/FCF
22.60 26.10 (3.96) (2.28) (3.42) (0.78) (2.15) (1.64) (2.07) (1.38)
Quick Ratio
0.34 0.34 1.61 1.47 0.06 3.00 1.39 2.67 0.12 0.03
Current Ratio
0.43 0.43 1.77 1.64 1.85 3.08 1.68 2.91 0.25 0.03
Net Debt/EBITDA
(0.50) (0.56) 1.06 0.75 (0.68) 0.36 (0.32) (1.42) (0.40) (0.42)
Debt/Assets
19.58% 19.29% 4.94% 6.13% 14.00% 14.65% 18.01% 19.73% 153.18% 1,235.53%
Debt/Equity
0.55 0.54 0.13 0.17 2.13 0.22 0.28 0.62 (1.06) (0.44)
Asset Turnover
0.28 0.25 0.32 0.27 0.05 0.09 0.52 0.48 0.01 0.13
Operating CF/Net income
0.31 0.31 0.86 0.76 0.55 (70.31) 1.49 1.67 0.27 0.35
Capex/Depreciation
(0.38) 0.00 (2.12) (2.11) (3.17) (1.06) (4.22) (6.15) (1.34) (0.13)
Interest Coverage
(4.59) — (4.70) (5.37) (26.07) (90.27) (13.00) (5.13) (21.46) (8.82)
ROE
(92.92%) (87.57%) (85.53%) (79.78%) (146.95%) 3.78% (39.52%) (43.98%) (1,368.97%) 164.62%
ROA
(33.72%) (31.02%) (31.72%) (29.60%) (29.00%) 1.30% (26.25%) (19.75%) (104.97%) (605.73%)
ROIC
(38.12%) 0.00% (57.52%) (64.80%) (74.42%) (322.83%) (24.17%) (15.55%) 0.00% 0.00%
Return on Tangible Assets
273.91% 273.91% (73.01%) (94.62%) (63.11%) 3.01% (87.36%) (27.96%) 509.96% 188.28%
Average Days of Receivables
79.95 79.95 218.98 182.74 190.50 155.22 158.47 366.60 376.02 14.11
Research and Development Expense of Revenue
24.56% 23.47% 34.65% 38.50% 346.06% 1,089.69% 100.75% 60.88% 2,004.34% 929.66%
Selling, General and Administrative Expense of Revenue
91.08% 91.08% 87.39% 89.17% 293.69% 247.95% 41.43% 43.27% 6,629.06% 1,432.08%
Intangible Assets out of Total Assets
0.65 0.65 0.42 0.43 0.09 0.28 0.34 0.20 0.59 0.00
Share Based Compensation of Revenue
33.34% 0.00% 23.39% 24.86% 146.14% 260.00% 4.92% 2.73% 87.36% 308.60%
Graham Net Nets
(0.40) (0.34) (0.19) (0.30) (0.11) 0.26 0.07 (0.32) (2.20) (4.79)
Graham Number
0.00 0.00 0.00 0.00 28.28 111.89 0.00 0.00 45.95 48.05
Earnings Yield
(35.31%) (30.21%) (22.92%) (35.17%) 19.96% 49.99% (25.69%) (24.74%) (263.70%) (608.99%)
Free Cash Flow Yield
4.83% 4.14% (21.71%) (36.51%) (34.09%) (82.93%) (49.68%) (75.41%) (118.65%) (217.87%)
Revenue per Share
10.42 1.04 13.95 15.33 2.45 3.59 14.63 14.35 0.18 0.25
Operating CF per Share
(3.96) (0.40) (11.73) (12.53) (8.31) (36.61) (11.07) (9.93) (5.11) (4.06)
Capex per Share
(1.01) 0.00 (4.15) (4.55) (7.57) (0.71) (3.24) (4.85) (0.72) (0.06)
Free Cash Flow per Share
(4.97) (0.40) (15.88) (17.09) (15.89) (37.32) (14.31) (14.78) (5.84) (4.12)
Cash per Share
3.64 0.36 12.30 11.22 0.36 21.37 2.46 2.54 0.51 0.16
Shareholders Equity per Share
14.59 1.46 21.42 20.00 3.82 24.73 15.91 11.58 (7.23) (8.91)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
14.59 1.46 21.42 20.00 3.82 24.73 15.91 11.58 (7.23) (8.91)
Free Cash Flow
(4.81) (3.83) (21.24) (22.85) (25.27) (79.56) (34.73) (37.09) (16.93) (17.34)
Working Capital
(9.62) (9.62) 13.15 10.90 35.91 33.79 10.39 30.41 (12.33) (26.16)
Capital Expenditures
(0.97) (0.97) (5.56) (6.09) (12.05) (1.52) (7.87) (12.17) (2.10) (0.26)
Net Current Asset Value
(18.45) (14.85) (16.50) (19.07) (8.07) 25.12 4.55 (15.54) (31.46) (38.12)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.10 0.00 0.30 0.30 3.09 0.20 0.22 0.34 3.95 0.25
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.51 0.51 0.22 0.23 1.65 0.47 0.18 0.09 1.06 3.61
Cash ROIC
(18.89%) (15.13%) (43.49%) (49.37%) (128.92%) (72.54%) (62.71%) (69.49%) (607.57%) 86.03%
Accounts Receivable Turnover
4.64 4.57 2.78 1.91 0.63 2.89 3.80 1.40 0.03 3.53
Accounts Payable Turnover
1.61 2.18 2.80 2.87 2.77 11.83 5.28 1.06 1.14 0.20
Inventory Turnover
12.10 11.79 8.80 7.09 15.61 523.28 241.87 43.13 81.23 0.00
Average Days of Payables
209.87 167.13 128.28 138.88 144.53 37.59 52.17 314.94 384.20 2,484.39
Days of Inventory on Hand
38.88 30.96 58.54 50.30 3.54 0.80 1.18 8.53 1.98 0.00
Average Receivables
2.17 2.21 6.70 10.73 6.15 2.64 9.33 25.80 18.36 0.29
Average Payables
4.23 3.91 3.86 4.19 5.07 7.10 6.94 4.83 5.51 9.85
Average Inventory
0.56 0.73 1.23 1.70 0.90 0.16 0.15 0.12 0.08 —
Average Assets
36.68 39.87 57.66 74.66 83.19 85.09 68.76 75.38 52.74 7.95
Average Common Equity
13.31 14.12 21.39 27.70 16.41 29.40 45.68 33.85 4.04 (29.26)

Fold the line items

Columns are period end dates